The patent myth pharmaceutical leaders still believeuntil it changes overnight.
For years, many in pharma have operated on a comforting assumption: if a drugs patent looks stable, the rest of the market should behave predictably. That assumption shows …

Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…

Your Paragraph IV strategy isnt failing because youre late. Its failing because the rules are designed to be anticipated.
The industry loves to talk about Paragraph IV filings as if theyre a chess match: a brands patents are static, and generics find t…

Stop chasing blockbusters. The real value is in unloved orphan drug patents.
Pharma has a habit of romanticizing the obvious bet: one blockbuster, one headline, one global franchise. Its a compelling storyand a dangerous one. Because in todays market, …

Your regulatory team cant afford to think like a silo.
If youre sitting in regulatoryplanning submissions, managing device-to-drug nuances, coordinating labeling, responding to information requeststhe temptation is to treat patent issues as legals prob…

Most drug companies treat patent intelligence like a fire extinguisher: something you grab only after a threat appearsoften right when a program is already late, costly, and politically fragile.
Thats the late pivot tax. Its the hidden cost of discov…

Bioequivalence is the easy part. The real cliff is Freedom to Operate.
If youve spent any time in pharmaespecially generics and biosimilarsyouve heard some version of this line: Once you show bioequivalence, youre basically done. In practice, that be…

A single bad Paragraph IV can cost a generic drugmaker $50 millionheres how.
If you think Paragraph IV litigation is just a legal exercise, this story should change your mind.
On its face, a Paragraph IV notice letter is supposed to be clean, precise, …